Mediscience nears tests for optical detector in US cervical cancer trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given Mediscience Technology the all-clear to begin a multicentre pilot trial of its cervical cancer detector, a fluorescence-based optical device called the Cancer Diagnostic-Ratiometer (CD-R). The study will aim to determine the device's efficacy at distinguishing between tissues that are normal, benign, precancerous low grade, precancerous high grade, carcinoma in situ and cancer; the device's real-time results will be compared with those for Pap tests and biopsies. It will also assess any adverse events. Last month, Cherry Hill, New Jersey-based Mediscience said that it had teamed up with New York firm Alfanix Technology to construct the CD-R and other photonics devices for cancer diagnostics, and to introduce the devices into Latin America for testing on humans.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.